





Improving Outcomes from Castration Resistant Prostate Cancer

Clinical States in Prostate Cancer




The Shifting Landscape of Systemic Therapy for CRPC: Positive Phase 3 Trials





1999
Median survival from time of first chemotherapy = 12.3 months




2012
Median survival from time of first chemotherapy = 32.6 months

	787	765	600	361	152	65	32	17	12	4	2
Abiraterone acetate	787	765	600	361	152	65	32	17	12	4	2
Placebo	397	378	275	149	63	26	11	5	4	2	2

Docetaxel + Novel Therapies

Target	Agent	N	1º End Point	Result
VEGF	Docetaxel ± bevacizumab (NCT00110214)	1,050	OS	OS not improved HR, 0.91; 95% CI, 0.78 to 1.05
VEGF	Docetaxel ± afibercept (NCT00519285)	1,224	OS	OS not improved HR, 0.94; 95% CI, 0.82 to 1.08
Endothelin Receptor A	Docetaxel ± atrasentan (NCT00134056)	991	OS and PFS	OS not improved HR, 1.01; 95% CI, 0.87 to 1.18
Endothelin Receptor A	Docetaxel ± zibotentan (NCT00617669)	1,052	OS	OS not improved HR, 1.00; 95% CI, 0.84 to 1.18
Src Kinase	Docetaxel ± dasatinib (NCT00744497)	1,380	OS	OS not improved HR, 0.99; 95% CI, 0.87 to 1.13
Immune	Docetaxel ± GVAX (NCT00133224)	408	OS	OS inferior HR, 1.70; 95% CI, 1.15 to 2.53
Immune	Docetaxel ± lenalidomide (NCT00988208)	1,059	OS	OS inferior HR, 1.53; 95% CI, 1.17 to 2.00
Vitamin D	Docetaxel ± calcitriol (NCT00273338)	953	OS	OS inferior HR, 1.42; 95% CI, 1.13 to 1.86
Clusterin	Docetaxel ± custirsen (NCT01188187)	1000	OS	OS not improved HR, 0.93; P = 0.207

Cabozantinib: Overall Survival Phase 3 Results



Improving Outcomes from Castration Resistant Prostate Cancer

- Molecular Pathology
 - *Mark Rubin*
- Improving the Treatment of CRPC: Drugs, Sequencing and Stratification
 - *Karim Fizazi*
- Circulating Biomarkers in Metastatic Prostate Cancer
 - *Kim Nguyen Chi*
- Imaging Metastatic Castration Resistant Prostate Cancer
 - *Anwar Padhani*